Kymera Therapeutics Inc. Common Stock vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while State Street Real Estate Select Sector SPDR ETF trades at $41.83 (market cap $7.83B). The key difference: Kymera Therapeutics Inc. Common Stock and State Street Real Estate Select Sector SPDR ETF are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and State Street Real Estate Select Sector SPDR ETF for 77 Days on average.
| KYMR | XLRE | |
|---|---|---|
Market Cap | $8.87B | $7.83B |
Volume | 779,107 | 5,853,296 |
Sector | Health | Sector/Thematic |
52-Week High | $127.31 | $46.01 |
52-Week Low | $55.80 | $40.01 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $8.26B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.83, down 0.21% on the day. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Key financial ratios are not available in the provided data. Recent news highlights the fund's low expense ratio of 0.08% and its focus on 30 U.S. large-cap real estate holdings, positioning it as a cost-effective domestic real estate exposure tool.
The outlook for XLRE is influenced by competing factors: its low-cost structure is a strength, but the sector faces headwinds from rising bond yields and potential interest rate volatility. Investment opportunity lies in its role as a pure-play U.S. real estate ETF, while risks include macroeconomic sensitivity and competition from more diversified or thematic real estate funds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →